CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD

Neurobiology of Aging

Volumn 38, Issue , 2016, Pages 47-55

  Gispert, Juan Domingo ^a,b   Monté, Gemma C ^c,d   Falcon, Carles ^a,b   Tucholka, Alan ^a   Rojas, Santiago ^a   Sánchez Valle, Raquel ^c   Antonell, Anna ^c   Lladó, Albert ^c   Rami, Lorena ^c   Molinuevo, José Luis ^a,c  

^a Clinical Research Program   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Astrocyte; Astrocytosis; Astroglia; Astrogliosis; Glia; Magnetic resonance imaging (MRI); Microglia; Microgliosis; Neuroimaging; Neuroinflammation; Tau; Voxel based morphometry (VBM)

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; GLYCOPROTEIN; PTAU181; TAU PROTEIN; UNCLASSIFIED DRUG; YKL 40 PROTEIN; CHI3L1 PROTEIN, HUMAN; CHITINASE 3 LIKE PROTEIN 1;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN; CEREBELLUM; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEMENTIA; FEMALE; FRONTAL CORTEX; GLIA; GRAY MATTER; HUMAN; INSULA; MALE; MILD COGNITIVE IMPAIRMENT; MORPHOMETRICS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SUPRAMARGINAL GYRUS; ASTROCYTE; CEREBROSPINAL FLUID; COGNITIVE DYSFUNCTION; INFLAMMATION; MIDDLE AGED; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ASTROCYTES; BIOMARKERS; CHITINASE-3-LIKE PROTEIN 1; COGNITIVE DYSFUNCTION; FEMALE; GRAY MATTER; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROGLIA; NEUROIMAGING; TAU PROTEINS;

EID: 84962257093     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.10.022     Document Type: Article

References (39)

1. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
2. Alcolea D., Carmona-Iragui M., Suarez-Calvet M., Sanchez-Saudinos M.B., Sala I., Anton-Aguirre S., Blesa R., Clarimon J., Fortea J., Lleo A. Relationship between beta-secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. J. Alzheimers Dis. 2014, 42:157-167.
3. Alcolea D., Vilaplana E., Pegueroles J., Montal V., Sanchez-Juan P., Gonzalez-Suarez A., Pozueta A., Rodriguez-Rodriguez E., Bartres-Faz D., Vidal-Pineiro D., Gonzalez-Ortiz S., Medrano S., Carmona-Iragui M., Sanchez-Saudinos M., Sala I., Anton-Aguirre S., Sampedro F., Morenas-Rodriguez E., Clarimon J., Blesa R., Lleo A., Fortea J. Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease. Neurobiol. Aging 2015, 36:2018-2023.
4. Antonell A., Fortea J., Rami L., Bosch B., Balasa M., Sanchez-Valle R., Iranzo A., Molinuevo J.L., Llado A. Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. J. Neural Transm. 2011, 118:259-262.
5. Antonell A., Mansilla A., Rami L., Llado A., Iranzo A., Olives J., Balasa M., Sanchez-Valle R., Molinuevo J.L. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. J. Alzheimers Dis. 2014, 42:901-908.
6. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007, 38:95-113.
7. Ashburner J., Friston K.J. Voxel-based morphometry-the methods. Neuroimage 2000, 11(6 Pt 1):805-821.
8. Ashburner J., Friston K.J. Unified segmentation. Neuroimage 2005, 26:839-851.
9. Bonneh-Barkay D., Bissel S.J., Kofler J., Starkey A., Wang G., Wiley C.A. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol. 2012, 22:530-546.
10. Bonneh-Barkay D., Bissel S.J., Wang G., Fish K.N., Nicholl G.C., Darko S.W., Medina-Flores R., Murphey-Corb M., Rajakumar P.A., Nyaundi J., Mellors J.W., Bowser R., Wiley C.A. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am. J. Pathol. 2008, 173:130-143.
11. Bonneh-Barkay D., Wang G., Laframboise W.A., Wiley C.A., Bissel S.J. Exacerbation of experimental autoimmune encephalomyelitis in the absence of breast regression protein 39/chitinase 3-like 1. J. Neuropathol. Exp. Neurol. 2012, 71:948-958.
12. Bonneh-Barkay D., Wang G., Starkey A., Hamilton R.L., Wiley C.A. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J. Neuroinflammation 2010, 7:34.
13. Burnham K.P., Anderson D.R. Model selection and multimodel inference: a practical information-theoretic approach 2002, Springer Science & Business Media, New York.
14. Carter S.F., Scholl M., Almkvist O., Wall A., Engler H., Langstrom B., Nordberg A. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J. Nucl. Med. 2012, 53:37-46.
15. 11C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. Eur. J. Nucl. Med. Mol. Imaging 2014, 41:2120-2126.
16. Craig-Schapiro R., Perrin R.J., Roe C.M., Xiong C., Carter D., Cairns N.J., Mintun M.A., Peskind E.R., Li G., Galasko D.R., Clark C.M., Quinn J.F., D'Angelo G., Malone J.P., Townsend R.R., Morris J.C., Fagan A.M., Holtzman D.M. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol. Psychiatry 2010, 68:903-912.
17. Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., DeKosky S.T., Gauthier S., Selkoe D., Bateman R., Cappa S., Crutch S., Engelborghs S., Frisoni G.B., Fox N.C., Galasko D., Habert M.O., Jicha G.A., Nordberg A., Pasquier F., Rabinovici G., Robert P., Rowe C., Salloway S., Sarazin M., Epelbaum S., de Souza L.C., Vellas B., Visser P.J., Schneider L., Stern Y., Scheltens P., Cummings J.L. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014, 13:614-629.
18. Dubois B., Picard G., Sarazin M. Early detection of Alzheimer's disease: new diagnostic criteria. Dialogues Clin. Neurosci. 2009, 11:135-139.
19. Eikelenboom P., Veerhuis R., van Exel E., Hoozemans J.J., Rozemuller A.J., van Gool W.A. The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. Curr. Alzheimer Res. 2011, 8:142-150.
20. Fortea J., Sala-Llonch R., Bartres-Faz D., Llado A., Sole-Padulles C., Bosch B., Antonell A., Olives J., Sanchez-Valle R., Molinuevo J.L., Rami L. Cognitively preserved subjects with transitional cerebrospinal fluid ss-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas. Biol. Psychiatry 2011, 70:183-190.
21. Gispert J.D., Rami L., Sanchez-Benavides G., Falcon C., Tucholka A., Rojas S., Molinuevo J.L. Nonlinear cerebral atrophy patterns across the Alzheimer's disease continuum: impact of APOE4 genotype. Neurobiol. Aging 2015, 36:2687-2701.
22. Glodzik L., Mosconi L., Tsui W., de Santi S., Zinkowski R., Pirraglia E., Rich K.E., McHugh P., Li Y., Williams S., Ali F., Zetterberg H., Blennow K., Mehta P., de Leon M.J. Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly. Neurobiol. Aging 2012, 33:1215-1227.
23. Heneka M.T., Carson M.J., El Khoury J., Landreth G.E., Brosseron F., Feinstein D.L., Jacobs A.H., Wyss-Coray T., Vitorica J., RansohoffR.M., Herrup K., Frautschy S.A., Finsen B., Brown G.C., Verkhratsky A., Yamanaka K., Koistinaho J., Latz E., Halle A., Petzold G.C., Town T., Morgan D., Shinohara M.L., Perry V.H., Holmes C., Bazan N.G., Brooks D.J., Hunot S., Joseph B., Deigendesch N., Garaschuk O., Boddeke E., Dinarello C.A., Breitner J.C., Cole G.M., Golenbock D.T., Kummer M.P. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015, 14:388-405.
24. Jack C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., Thies B., Phelps C.H. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:257-262.
25. Klein A., Andersson J., Ardekani B.A., Ashburner J., Avants B., Chiang M.C., Christensen G.E., Collins D.L., Gee J., Hellier P., Song J.H., Jenkinson M., Lepage C., Rueckert D., Thompson P., Vercauteren T., Woods R.P., Mann J.J., Parsey R.V. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. NeuroImage 2009, 46:786-802.
26. Molinuevo J.L., Gispert J.D., Dubois B., Heneka M.T., Lleo A., Engelborghs S., Pujol J., de Souza L.C., Alcolea D., Jessen F., Sarazin M., Lamari F., Balasa M., Antonell A., Rami L. The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study. J. Alzheimers Dis. 2013, 36:67-77.
27. Moller C., Vrenken H., Jiskoot L., Versteeg A., Barkhof F., Scheltens P., van der Flier W.M. Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease. Neurobiol. Aging 2013, 34:2014-2022.
28. Olsson B., Hertze J., Lautner R., Zetterberg H., Nagga K., Hoglund K., Basun H., Annas P., Lannfelt L., Andreasen N., Minthon L., Blennow K., Hansson O. Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. J. Alzheimers Dis. 2013, 33:45-53.
29. Perrin R.J., Craig-Schapiro R., Malone J.P., Shah A.R., Gilmore P., Davis A.E., Roe C.M., Peskind E.R., Li G., Galasko D.R., Clark C.M., Quinn J.F., Kaye J.A., Morris J.C., Holtzman D.M., Townsend R.R., Fagan A.M. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 2011, 6:e16032.
30. Reiman E.M., Jagust W.J. Brain imaging in the study of Alzheimer's disease. Neuroimage 2012, 61:505-516.
31. Rejman J.J., Hurley W.L. Isolation and characterization of a novel 39 kilodalton whey protein from bovine mammary secretions collected during the nonlactating period. Biochem. Biophys. Res. Commun. 1988, 150:329-334.
32. Rosen C., Andersson C.H., Andreasson U., Molinuevo J.L., Bjerke M., Rami L., Llado A., Blennow K., Zetterberg H. Increased levels of chitotriosidase and YKL-40 in cerebrospinal fluid from patients with Alzheimer's disease. Dement. Geriatr. Cogn. Dis. Extra 2014, 4:297-304.
33. Sheline Y.I., Raichle M.E. Resting state functional connectivity in preclinical Alzheimer's disease. Biol. Psychiatry 2013, 74:340-347.
34. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
35. Sutphen C.L., Jasielec M.S., Shah A.R., Macy E.M., Xiong C., Vlassenko A.G., Benzinger T.L., Stoops E.E., Vanderstichele H.M., Brix B., Darby H.D., Vandijck M.L., Ladenson J.H., Morris J.C., Holtzman D.M., Fagan A.M. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol. 2015, 72:1029-1042.
36. Tarawneh R., Head D., Allison S., Buckles V., Fagan A.M., Ladenson J.H., Morris J.C., Holtzman D.M. Cerebrospinal fluid markers of neurodegeneration and rates of brain atrophy in early Alzheimer disease. JAMA Neurol. 2015, 72:656-665.
37. Thal D.R., Griffin W.S., de Vos R.A., Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol. 2008, 115:599-609.
38. Varley J., Brooks D.J., Edison P. Imaging neuroinflammation in Alzheimer's and other dementias: recent advances and future directions. Alzheimers Dement. 2014, 11:1110-1120.
39. Wiley C.A., Bonneh-Barkay D., Dixon C.E., Lesniak A., Wang G., Bissel S.J., Kochanek P.M. Role for mammalian chitinase 3-like protein 1 in traumatic brain injury. Neuropathology 2015, 35:95-106.